TP53 and glioma: In addition, in glioma patients, several studies have indicated that at least one aberrant pathway among the RTK/PI3K/AKT, TP53 and RB1 signaling pathways was identified in 80-90% of glioblastomas 30, 31, which highlights their potential as therapeutic targets.